Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma
- PMID: 22966365
- PMCID: PMC3436408
- DOI: 10.3892/ol_00000121
Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma
Abstract
We investigated the matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) proteins in transitional cell carcinoma (TCC) cell lines and surgical specimens of the bladder neoplasm. The expression level was correlated to the degree of cellular differentiation and invasiveness of bladder cancer. Panels of six TCC cell lines with different degrees of differentiation were tested with monoclonal antibodies (mAbs) to MMP-1, MMP-2, MMP-3, MMP-9a, MMP-9b, TIMP-1 and TIMP-2 by immunocytochemistry. Gelatin zymography was also conducted on the cell lines for MMP-2 and -9. In addition, immunohistochemistry with the mAbs to MMP and TIM molecules was performed on 30 TCC specimens. We found that TCC cell lines were stained positively for MMP-1 (6/6), weakly for MMP-9a (2/6), MMP9b (5/6) and TIMP-1 (3/6), and negatively for MMP-2 (3/6) and MMP-3 (3/6). Zymographic analysis of the cell lines showed a high level of MMP2 in the MGH-U4 cell line. In bladder cancer surgical specimens, all specimens were positive for MMP1 (30/30), 19 were positive for MMP-2 (63.3%), 21 positive for MMP-9a (70%) and 15 positive for MMP-9b (50%). The expression of MMP-2 was found to be positively correlated with higher-grade tumors (p=0.036) and the expression of MMP-9a and -9b was found to be positively correlated with tumor stage (p=0.012 and 0.023, respectively). However, the expression of MMP-1, MMP-3, TIMP-1 and TIMP-2 was not correlated with either tumor staging or grading. In conclusion, the expression of MMP-2 and -9 was correlated with high-grade or high-stage bladder tumors, respectively. However, this correlation was not observed with TCC cell lines in which high- and low-grade tumors are included. Immunohistochemical results on tumor lesions may have more clinical relevance, since in a given tumor microenvironment the interaction among tumor cells in situ and tumor-associated cells, such as neutrophils, macrophages, lymphocytes and endothelial cells, as well as environmental factors (hypoxia and pH), cytokines and growth factors released by these cells may be required for TCC to express selective MMPs and TIMPs. The selective expression of these molecules then regulates tumor progression.
Figures

Similar articles
-
Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.Int J Oncol. 2000 Oct;17(4):673-81. Int J Oncol. 2000. PMID: 10995877
-
Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.Cancer. 2002 Mar 1;94(5):1466-75. doi: 10.1002/cncr.10355. Cancer. 2002. PMID: 11920503
-
Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.BMC Cancer. 2009 Jan 14;9:20. doi: 10.1186/1471-2407-9-20. BMC Cancer. 2009. PMID: 19144199 Free PMC article.
-
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.J Pathol. 2000 Jul;191(3):245-56. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#. J Pathol. 2000. PMID: 10878545
-
Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.Invasion Metastasis. 1998-1999;18(3):134-41. doi: 10.1159/000024506. Invasion Metastasis. 1998. PMID: 10474026
Cited by
-
Effect of TRPV2 cation channels on the proliferation, migration and invasion of 5637 bladder cancer cells.Exp Ther Med. 2013 Nov;6(5):1277-1282. doi: 10.3892/etm.2013.1301. Epub 2013 Sep 13. Exp Ther Med. 2013. PMID: 24223658 Free PMC article.
-
Gain of TPPP as a predictor of progression in patients with bladder cancer.Exp Ther Med. 2021 Nov;22(5):1204. doi: 10.3892/etm.2021.10638. Epub 2021 Aug 24. Exp Ther Med. 2021. PMID: 34584549 Free PMC article.
-
Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.Oncogene. 2015 Feb 12;34(7):890-901. doi: 10.1038/onc.2014.2. Epub 2014 Feb 24. Oncogene. 2015. PMID: 24561529 Free PMC article.
-
Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk.In Vivo. 2021 Sep-Oct;35(5):2535-2540. doi: 10.21873/invivo.12535. In Vivo. 2021. PMID: 34410940 Free PMC article.
-
Impact of tissue inhibitor of metalloproteinases-3 genetic variants on clinicopathological characteristics of urothelial cell carcinoma.J Cancer. 2023 Jan 22;14(3):360-366. doi: 10.7150/jca.81083. eCollection 2023. J Cancer. 2023. PMID: 36860920 Free PMC article.
References
-
- Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res. 1986;46:1–7. - PubMed
-
- Chuang CK, Liao SK. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinoma. Anticancer Res. 2003;23:4635–4640. - PubMed
-
- Brown PD, Levy AT, Margulies IMK, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 1990;50:6184–6191. - PubMed
-
- Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettline C, Menck HR. The national cancer data base report on bladder carcinoma. Cancer. 1996;77:1505–1513. - PubMed
-
- Chuang CK, Liao SK. Evaluation of CA19-9 as a tumor marker in urothelial malignancy. Scand J Urol Nephrol. 2004;38:359–365. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous